Drug name: LY2109761


Related CSCTT Targets

TGFBR1 [ref.1]P36897
TGFBR2 [ref.1]P37173

LY2109761

Cas.no PubChem ID
700874-71-1 11655119
Known Target
TGF-beta receptor type-1P36897
TGF-beta receptor type-2P37173
Introduction
LY2157299 is a small molecule inhibitor of the TGF-β receptor type I/type II kinases (IC50 = 69 nM). It has been used to study the role of TGF-β signaling in tumor cell migration and metastasis in pancreatic tumor cell lines where 5 μM of the compound completely disrupts Smad-2 phosphorylation, an immediate downstream target of the kinase activity. It can also suppress radiation-induced inflammatory cytokine signaling and proangiogenic genes, including ID1, in human primary fibrobalsts.

LY2109761-Structure

...

Reference

  • [1] Molecular definition of breast tumor heterogeneity.
    Shipitsin, M., et al. (2007).Cancer Cell. 11(3):259-73.. [ 17349583 ]

Back to top